11- Patents and Intellectual Property (S1E11)

Ever pick up a prescription and wonder how that
little pill got all the way from some scientist's
lab to your medicine cabinet? It's a journey,
right? Like years and years. And it costs a fortune.
We're talking hundreds of millions of dollars,
sometimes even billions. Crazy, right? So today
we're gonna go deep on one really important part
of that whole process, patents. They're like
these legal things, right? They protect drug
innovations and help companies, you know, get
all that money back that they invested. Right.
But how long do those things even last? Yeah.
And then what happens when they expire? And like,
what's the whole deal with generics? Right. That's
our deep dive today. It's fascinating because
it's these little pieces of paper, these patents,
they're actually what drives the whole engine
of drug development. Without them, we would probably
see a much slower pace of innovation. OK, so.
Back up a second for me. So I get that patents
are supposed to protect inventions, but how does
that even work with, you know, drugs and pharmaceuticals?
Well, think of it this way. You have brilliant
minds working in labs all over the world, spending
years, sometimes decades, researching and developing
new drugs. And these are incredibly risky ventures.
Yeah. Most experimental drugs never even make
it to market. Right. So there needs to be a reward
and incentive for companies to take on such a
gamble. And that incentive is the patent. Right.
Yeah. That's what it is. It gives them a monopoly,
essentially, at least for a while. Exactly. A
pharmaceutical patent grants a company exclusive
rights to produce and sell a new drug for a limited
period. This exclusivity allows them to set prices
and recoup their R &D costs without facing immediate
competition. It's like saying, hey, you invested
all this time and money, so you get a head start.
OK, so you get 20 years, but you spend eight
years just getting through trials and FDA approval
and all that. Suddenly, that window is feeling
a lot smaller. Precisely. The effect of patent
life for a drug is often much shorter than the
20 years on paper. And so companies are racing
against the clock to make the most of that time
before those generic competitors come knocking.
Ah, generics. Yeah. You know, sometimes at the
pharmacy they'll ask, do you want the brand name
or the generic? Yeah. Those are basically the
same drug. Right. Right, just cheaper. Right.
So how do patents even come into that equation?
Like, how does that even work? Once a patent
expires, other companies can swoop in and start
producing generic versions of the drug. And since
they didn't have to bear the burden of all that
initial research and development, they can sell
those generics at a fraction of the price. So
if it's literally the same drug, why wouldn't
everyone just get the generic? I mean, there's
got to be a catch, right? There are some nuances.
Sometimes there are very subtle differences in
the inactive ingredients or the way the drug
is released in the body. OK. But in many cases,
it's largely about peace of mind. Some people
just feel more comfortable sticking with the
brand name they know, even if it costs more.
I could see that. You know, you get used to a
certain pill and maybe you're a little wary of
switching. But like from a purely economic standpoint,
those generics are a total game changer. Absolutely.
Like, what does that even do for the company
that invented the drug. That's got to be a huge
shift for them. Absolutely. The entry of generics
can lead to a dramatic drop in sales for the
brand name drug. It's a classic case of balancing
innovation and affordability. So let's talk about
some challenges then. I mean, even when a drug
has patent protection, it's not always smooth
sailing. Right like I mean some drugs just have
these like unique Characteristics that might
need tweaking even after they're already on the
market and like our research mentioned this drug
Griza fulvin It's used for fungal infections
and has all these like quirks with the dosage
and how it dissolves Impacting how much your
body actually absorbs right? How does that play
into this whole patent game? I mean, that's got
to be tricky That's where things get really interesting,
right? So even with that precious patent protection,
companies might still face this urgency to improve
their drug, right? Take Rizofulven, for example.
Knowing that their patent window is limited,
they might be racing to make improvements, maybe
finding ways to enhance the formulation so more
of the drug gets absorbed, all while battling
the clock before generics hit the market. So
even with a patent, they're still under pressure
to innovate and refine. It never stops, really.
It's a constant push and pull. And it raises
a really important question. What happens when
that patent protection runs out? Especially for
drugs that treat rare diseases or maybe don't
have a huge market. That's when things can get
ethically tricky. And that's something we'll
dive into more in the next part of our deep dive.
Welcome back to our deep dive into the world
of pharmaceutical patents. Before we left off,
we were talking about how these patents incentivize
companies to invest in this like risky and expensive
process of developing new drugs. Yeah and we
were just getting to the part where things get
tricky like what happens when those patents expire
especially for medicines that treat like rare
diseases, or maybe just don't have a huge market.
You're about to say it gets ethically complicated.
It does. You see, developing a new drug, it's
not like creating the next hit song or designing
a cool new gadget. We're talking about potentially
life -saving treatments here. Right. So the stakes
are incredibly high, not just for the companies
involved, but for patients all over the world.
So if a shorter patent life might discourage
companies from investing in those, like, less
profitable areas, how do we balance that with
the need for people to actually get access to
these, like, crucial medications? It seems like
a real dilemma. It is, and that's where the regulatory
landscape comes in, right? With agencies like
the U .S. Patent and Trademark Office or USPTO
playing a crucial role. So the USPTO, they're
like the gatekeepers. They're the ones who decide
which inventions deserve patent protection. I'm
guessing that process is pretty intense. Oh,
absolutely. It's not just a rubber stamp. To
secure a patent, a new drug has to meet a whole
bunch of criteria. It has to be novel, meaning
it's truly something new and hasn't been done
before. It has to be non -obvious, meaning it's
not just a minor tweak to an existing invention.
And of course it has to be useful, right? It
can't just be a cool idea. In theory, it has
to actually work. So someone got rich arguing
over molecules. Wild. It happens more often than
you think. These patent battles can be incredibly
complex, with teams of scientists and lawyers
dissecting the tiniest details of a drug's composition
and how it's made. So it's not just lawyers arguing
contrast law. It gets super technical. Oh, for
sure. Expert witnesses are called in to debate
the molecular structures, analyze the manufacturing
techniques. It's a real battle of the scientific
minds. And these legal showdowns can have a huge
impact on the industry. I bet. Do we have any,
like... juicy examples of these high -profile
patent disputes in our research. We do. One that
always fascinates me is the case of omeprazole,
the drug you might know as Prilosec. It's that
popular heartburn medication, a proton pump inhibitor.
Prilosec. Yeah, I think I've seen commercials
for that. So what was the drama there? Well,
back in the 1980s, the company Astra, now AstraZeneca,
developed and patented omeprazole. OK. It was
a huge breakthrough for treating heartburn and
acid reflux and quickly became a blockbuster
drug. Naturally, when the patent neared its expiration
date, generic drug companies were ready to jump
in and offer their own versions. Sounds like
a showdown was brewing. It was. Astra fought
tooth and nail to defend their patents, filing
lawsuits against several generic companies, claiming
they were stepping on their intellectual property
rights. So these cases must have been incredibly
complex, like diving deep. into the chemistry
and all the little details of how the drug is
made. You got it. Think molecular structures,
manufacturing processes, the tiniest tweaks to
the formula. It was a legal and scientific labyrinth.
And in the end, Astra did win some of the cases,
delaying those generics from hitting the market
for a bit. But eventually, the patent did expire,
opening the door for more affordable options
for patients. So in the end, It's kind of a cycle,
right? A company innovates, gets patent protection,
makes their money back. Then eventually those
generics come in and kind of shake things up.
Exactly. And it highlights how crucial research
and development is for these pharmaceutical companies.
They know that even with a patent, they can't
just sit back and relax. They need to keep pushing
the boundaries, always seeking new and improved
treatments to stay ahead of the curve. It's like
an ongoing game of chess, constantly anticipating
the next move. That's a great analogy. And speaking
of strategy, there's another layer to this whole
patent game we need to talk about. Data exclusivity.
Okay, data exclusivity. Break that down for me.
How's that different from a patent? So imagine
a company spends years conducting clinical trials,
gathering all this valuable data to prove that
their new drug is safe and effective. Data exclusivity
grants them exclusive rights to that data for
a certain period of time, even if the patent
on the drug itself has expired. But doesn't that
mean It means that even if another company wants
to create a generic version, they can't simply
piggyback on that original data. They have to
conduct their own studies, which can be very
expensive and time consuming. Oh, interesting.
So it's another way for the company that did
all the initial legwork to maintain a competitive
edge for a little while longer. Exactly. And
it's been used quite strategically for a number
of those blockbuster drugs we were talking about
earlier. Are there any like? famous examples
of how this data exclusivity strategy played
out. Oh, absolutely. One that stands out is the
story of Prozac, the antidepressant that became
a household name. The company, Eli Lillian Company,
developed fluoxetine, the active ingredient in
Prozac, back in the 1970s. When their patent
was nearing expiration, they came up with a clever
strategy to extend their market dominance. OK,
spill the beans. What did they do? They decided
to pursue a new patent for a very specific use
of fluoxetine. Treating premenstrual dysphoric
disorder, or PMDD, basically they were repurposing
an existing drug for a new indication, a new
medical use. So it's like they found a new way
to use an existing tool and got rewarded for
that innovation. Exactly. And it wasn't just
a marketing ploy. They conducted clinical trials,
gathered evidence to support the effectiveness
of fluoxetine for treating PMDD, and ultimately
secured a new patent for this specific use. So
it seems like a win -win, right? They extended
the market exclusivity for Prozac, which could
potentially lead to even more research and development,
and they brought a new treatment option to patients
suffering from a condition that wasn't always
well addressed. Everyone benefits. That's one
way to look at it. But. But. There's a but coming,
isn't there? There's always a but. Well, this
strategy of repurposing drugs and getting new
patents for specific uses has also sparked a
fair bit of debate. OK, now I'm really intrigued.
What are the arguments against it? Critics often
call this practice evergreening, suggesting that
it's just a way for companies to artificially
extend their monopolies on drugs that are already
profitable. They argue that it stifles competition
and keeps drug prices high for longer, delaying
the availability of cheaper generics. I see.
So the argument is it's not really a groundbreaking
innovation. It's just a legal tactic to maintain
market dominance. Trixie. Exactly. And this debate
highlights the very fine line that regulators
and policymakers have to walk. It's a constant
balancing act, weighing the need to reward innovation
with the need to ensure that people can actually
afford the medications they need. So this whole
system, it's kind of built on the foundation
of tension. It is. And that tension plays out
on a global scale, too, which is something we'll
explore in the next part of our deep dive. The
question of how pharmaceutical patents affect
access to medicine around the world. That's a
big one. Yeah, that's a crucial conversation
to have, especially considering how wildly different
health care systems are around the globe. Absolutely.
The stakes are incredibly high and the implications
are far reaching. Welcome back to the deep dive.
We've been kind of untangling this whole world
of pharmaceutical patents, and it's gotten pretty
complex. It has, hasn't it? We've talked about
how those patents drive innovation, how they
impact affordability, and how they play this
crucial role in shaping access to medicines on
a global scale. Yeah. And like you were saying
before, things get even more complicated when
we zoom out and look at the global picture. How
do these patents even affect access to medicines
in different parts of the world, especially,
you know, places where healthcare might not be
as readily available or it might be more expensive.
Yeah, that's a crucial question. You see, a drug
that costs, let's say, a few hundred dollars
a month... might be manageable for someone with
good insurance in a high income country. But
for someone in a developing country, that same
price tag could be completely out of reach. It's
like having the cure, but only a select few can
even get it. Exactly. And patents play a big
role in that dynamic. It's a constant struggle
to balance the rights of those who own the patents,
those who invented the drugs, with the needs
of people who are desperately seeking treatment
but can't afford it. So what are some ways that
people are trying to fix that? How do you address
that global imbalance? Well, there are a few
different strategies that have emerged over the
years. One that's been fairly successful is tiered
pricing. Tiered pricing. Okay, that sounds kind
of familiar. Remind me, how does that work again?
It's basically a system where drug companies
offer different prices for the same drug in different
countries based on things like average income
levels or the overall strength of the healthcare
system. So lower income countries get like a
discount. Exactly. It's a recognition that a
one size fits all pricing model just doesn't
make sense in a world with such vast economic
disparities. One notable example is what happened
with HIV AIDS medications in the early 2000s.
Yeah, I vaguely remember hearing about that.
It was like a massive global crisis. It was.
And facing immense pressure from activists, governments,
and organizations like the World Health Organization,
pharmaceutical companies started offering tiered
pricing for their HIV AIDS drugs. Wow. And the
result was a dramatic increase in access to those
life -saving treatments in sub -Saharan Africa
and other regions where the epidemic was hitting
hardest. So it's like proof that these pricing
strategies can actually work. It really shows
how collaboration and creative solutions can
lead to positive change. But I'm guessing tiered
pricing isn't perfect. There's gotta be some
downsides, right? Oh, there are definitely challenges.
One concern is drug diversion. Imagine medications
intended for a lower -income country with a discounted
price end up being illegally sold in a wealthier
country at a markup. Oh, wow. That's terrible.
So you could have a situation where these drugs
are being taken away from the people who need
them the most and then sold back to the people
who can already afford them. Exactly. That's
why robust monitoring and distribution systems
are essential. to prevent that kind of exploitation.
Makes sense. So it sounds like striking a balance
is like a constant thing with this whole world
of pharmaceutical patents. It is. And another
strategy that's gaining traction is voluntary
licensing. OK. Voluntary licensing. What is that?
Think of it as a patent holder, like the pharmaceutical
company, saying, OK, we're willing to share.
They grant permission to other companies, often
generic drug manufacturers, to produce and sell
their patented drug. So they're basically letting
other people profit off of their invention. Why
would they do that? It's often done with a specific
goal in mind, like increasing access to a drug
in developing countries. Right. And it often
involves technology transfer as well, where the
original company shares the know -how and expertise
needed to ensure the generic versions meet quality
standards. Oh, that's cool. So it's kind of like
a collaboration, like a way to get those medicines
out there to more people without totally getting
rid of the patent system. Exactly. And it's been
used successfully for a number of key drugs.
One example is ritonavir, another HIV -AIDS medication.
Abbott Laboratories, the company that held the
patent, entered into voluntary licensing agreements
with several generic drug manufacturers in India
and South Africa, which led to a significant
drop in the price of Ritonavir in those regions
and beyond. So it's a way to bridge the gap between
protecting that intellectual property and making
sure that people who need it can get it. Absolutely.
And it speaks to the growing recognition that
global health challenges require global solutions.
So we've got tiered pricing, voluntary licensing.
Are there any other tools in the toolbox when
it comes to this whole patent thing? There are.
One that's particularly interesting is the concept
of patent pools. Patent pools. What are those?
Imagine a group of companies, all holding patents
related to, let's say, a specific disease or
area of medicine. OK. coming together and agreeing
to license those patents to each other or even
to third parties. It's like everyone's working
together to use those patents for a good cause.
Exactly. And it can be really beneficial in fields
where drug development relies on this complex
web of interconnected patents. It can streamline
the process, reduce legal hurdles, and ultimately
make it easier to get those treatments to the
people who need them. I can see how that would
be super helpful. Any examples of these patent
pools in action? There are. One that comes to
mind is the Medicine's Patent Pool, or MPP. It's
a UN -backed organization focused specifically
on increasing access to HIV, hepatitis C, and
tuberculosis treatments in developing countries.
Wow, those are some of the biggest ones out there.
How do they work? The MPP negotiates licensing
agreements with those who hold patents for key
drugs in those disease areas. Okay. And they
then grant sublistences to generic drug manufacturers,
allowing them to produce and distribute more
affordable versions of those medications in low
and middle -income countries. So they're kind
of like a matchmaker. Exactly. They connect the
people who own the patents to the people who
can make those drugs more affordable. Exactly.
And their work has had a profound impact, improving
the lives of countless people around the world.
great to see these different approaches, like
the tiered pricing, the voluntary licensing,
the patent pools. All these are actually being
used to address this really complex issue of
balancing those patent protections and global
access to medicine. It's a testament to the dedication
of governments, international organizations,
advocacy groups, and even the pharmaceutical
companies themselves. It shows that there's this
growing awareness of the need for solutions that
work for everyone. So that wraps up our deep
dive into the world of pharmaceutical patents.
We certainly covered a lot of ground. We've explored
how these patents drive innovation, how they
impact affordability, and how they play this
crucial role in shaping access to medicines on
this global scale. And hopefully our listeners
are walking away with a better understanding
of this whole complex world and how it affects
them, no matter where they live. Remember, knowledge
is power, especially when it comes to your health.
The more we understand about how things work,
the better equipped we are to ask the right questions
and advocate for solutions that benefit everyone.
We always encourage our listeners to keep digging
deeper into these topics that spark their interest.
Don't be afraid to do your own research, reach
out to experts, get involved in the conversation.
And until next time, keep those minds curious.